Abstract
Collagenase Clostridium histolyticum (CCH) was approved both in the United States (US) and Europe (EU) for adults with Dupuytren contracture (DC) [18] for the non-surgical treatment of a single palpable cord and has become a good alternative to surgical correction of DC. The dose suggested for a single treatment is 0.58 mg. In case additional treatment is required, the next injections are given after 30 days. However, recent studies revealed that treatment of multiple joints using two concurrent injections resulted in comparable improvement to those seen in previous studies. Multiple 0.58 mg concurrent injections is approved in the US for effective treatment of patients with multiple affected joints would benefit the patient and enhance the cost-effectiveness of the drug, which is otherwise currently a challenge (Fig. 5.1). Dividing a single dose of CCH into aliquots is an alternative successful treatment of complex combined cords like the “Y” cord (Fig. 5.2). A single dose can also be divided to treat two separate cords that are not connected (Fig. 5.3). However, success will be determined by the thickness of the cords, since the volume splitting will only work if they are very thin with a small cross-sectional diameter.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Badalamente M, Hurst L, Henz VR. Collagen as a clinical target: non operative treatment of Dupuytren’s disease. J Hand Surg Am. 2002;27:788–98.
Bendon CL, Giele HP. Collagenase for Dupuytren’s disease of the thumb. J Bone Joint Surg Br. 2012;94:1390–2.
Bulstrode NW, Lemec B, Smith PJ. The complications of Dupuytren’s contracture surgery. J Hand Surg Am. 2005;30:1021–5.
Coleman S, Gilpin D, Tursi J. Multiple concurrent collagenase clostridium Hystoliticum injections to Dupuytren’s cords: an exploratory study. BMC Muscoloskelet Disord. 2012;13:61–8.
Denkler K. Surgical complications associated with fasciectomy for Dupuytren’s disease: a 20-year review of the English literature. Eplasty. 2010;10:116–33.
Leclercq C. Fasciotomy. In: Tubiana R, Leclercq C, Hurst LC, et al., editors. Dupuytren’s disease. Malden: Blackwell Science; 2000. p. 132–9.
Sennwalk GR. Fasciectomy for treatment of Dupuytren’s disease and early complications. J Hand Surg Am. 1990;15:755–61.
Verheyden JR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur Vol. 2015;40:133–40.
Skirven TM, Bachoura A, Jacoby SM, Culp RW, Osterman AL. The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by Dupuytren disease and treated with collagenase injection. J Hand Surg. 2013;38A:684–9.
Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman GJ, Tursi JP, Hurst LC. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 2015;40(10):1963–71.
Hirata H, Tanaka K, Sakai A, Kakinoki R, Ikegami H, Tateishi N. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren’s contracture in non-Caucasian Japanese patients (CORD-J Study): the first clinical trial in a non-Caucasian population. J Hand Surg Eur Vol. 2017;42:30–8.
Pajardi G. Chirurgia e riabilitazione della mano. Padova: Ed. Piccin; 2014.
Felici N, Marcoccio I, Giunta R, Hearle M, Leclercq C, Pajardi G, Wilbrand S, Georgescu AV, Press G. Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence. Handchir Mikrochir Plast Chir. 2014;46(6):359.a.
Warwick D, Arner M, Pajardi G, Reichert B, Szabo Z, Masmejean E, Fores J, Chapman DS, Gerber RA, Huard F, Seghouani A, Szczypa PP. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open label study of clinical and patient-reported outcomes. J Hand Surg Eur Vol. 2015;40(2):124–32.
Warwich D, Arandes-Renù JM, Pajardi G, Witthaut J, Hurst LC. Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50:251–61.
Verhayden JR. Early outcomes of a sequential series of 144 patient with Dupuytren’s disease treated by collagenase injection using an increased dose, multicord technique. J Hand Surg. 2015;40:133–40.
RCP Xiapex Riassunto delle Caratteristiche del Prodotto, 05-2016.
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J, CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968–79.
Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am. 2007;32:767–74.
Rodriguez JR, Zhang W, Scammell BE, TRC D. Dynamism in Dupuytren’s contractures. J Hand Surg. 2015;40E:166–70.
Coleman S, Gilpin D, Kaplan FT, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57–64.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Pajardi, G., Parolo, C. (2018). Preparation, Injection and Traction Procedures (Pearls and Tips and Tricks): Technical Evolution and Results in Severe Cases. In: Pajardi, G., Badalamente, M., Hurst, L. (eds) Collagenase in Dupuytren Disease . Springer, Cham. https://doi.org/10.1007/978-3-319-65822-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-65822-3_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65821-6
Online ISBN: 978-3-319-65822-3
eBook Packages: MedicineMedicine (R0)